sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
»ùÒòÐÞÊÎÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÐÄѪ¹Üϵͳģ×Ó > »ùÒòÐÞÊÎÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×Ó

ǰÑÔ

ÐÄÁ¦Ë¥½ß(heart failure, HF)ÊÇÖ¸ÐÄÔà±ÃѪÄÜÁ¦¼õÍË £¬²»¿É²«³öÓë¾²Âö»ØÁ÷¼°ÉíÌå×éÖ¯´úлËùÐèÏ൱µÄѪҺ¹©Ó¦ £¬Í¬Ê±¾²ÂöϵͳÓÙѪµÄ²¡ÀíÀú³Ì¡£³£ÓÉÖÖÖÖ¼²²¡ÒýÆðÐļ¡Ëõ¶ÌÄÜÁ¦Ï÷Èõ £¬´Ó¶øÊ¹ÐÄÔàµÄѪҺÊä³öÁ¿ïÔÌ­ £¬È±·¦ÒÔÖª×ã»úÌåµÄÐèÒª £¬²¢Óɴ˱¬·¢Ò»ÏµÁÐÖ¢×´ºÍÌåÕ÷¡£¿É·ÖΪѹÁ¦³¬¸ººÉÒýÆðµÄÐÄÁ¦Ë¥½ßѪÈÝÅú³¬¸ººÉÒýÆðµÄÐÄÁ¦Ë¥½ß¡¢»¯Ñ§ÒòËØÒýÆðµÄÐÄÁ¦Ë¥½ß¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ £»úÖÆ¡¿£º

ÀíÂÛÉϽ² £¬Ê¹ÓÃת»ùÒòÊÖÒÕʹijÖÖÒò×ÓÔÚÐļ¡ÖÐÌ«¹ý±í´ï £¬»òʹÓûùÒòÇóýÊÖÒÕʹÓëÐļ¡Ëõ¶Ì¹¦Ð§Ç×½üÏà¹ØµÄ»ùÒòȱʧ £¬¿Éµ¼ÖÂÐÄË¥¡£Ð¡Êó»ùÒòÓëÈËÀà¿¿½ü £¬²¢Ò×±»¸Ä±ä £¬ÇҸıäºóµÄ»ùÒò±í´ïÏà¶ÔÎȹÌ¡£ÏÖÔËÓûùÒòÇÃÈë¡¢ÌÞ³ý¼°×ÌÈÅÊÖÒÕ £¬Ê¹ÐÄÔàÌØÒì»ùÒò±í´ï¸Ä±ä £¬¿É½¨ÉèСÊó»ùÒòÐÞÊÎÐÔÐÄÁ¦Ë¥½ßÄ£×Ó¡£

¡¾ÔìÄ£ÌØµã¡¿£º

¼¡ÈâlimÂѰ׻ùÒòÇóýСÊ󣺼¡ÈâlimÂѰ×(muscle LIM protein, MLP£©µ÷Àí¼¡Èâ·Ö½â £¬ÌÞ³ýMLP»ùÒòµÄ´¿ºÏ×ÓСÊ󽫷ºÆðÓëÀ©ÕÅÐÍÐÄ ¼¡²¡ÀàËÆµÄ±íÐÍ £¬²¢ÓÐÐļ¡·Ê´ó¡¢¼äÖÊϸ°ûÔöÉúºÍÏËά»¯ £¬µ½³ÉÄêÉú³¤ÎªHF £¬ÓÐÓëÈËÀàHF½üËÆµÄѪÁ÷¶¯Á¦Ñ§ºÍÁÙ´²ÌåÕ÷¡£ÆäÌØµãÊÇ×óÊÒ¹¦Ð§²»È« £¬éæÃü¡£¼¡ÈâlimÂѰ׻ùÒòÌÞ³ýСÊó×÷ΪÐÄË¥µÄÒÅ´«Ä£×Ó±»Ðí¶àʵÑéÊÒÓÃÀ´Ì½Ë÷ÐÄË¥ºÍÀ©ÐIJ¡µÄ·Ö×ÓÖÎÁÆÒªÁì¡£

¸Æµ÷ÂѰ׼¤Ã¸¢òת»ùÒòСÊ󣺸Ƶ÷ÂѰ׼¤Ã¸¢ò(calmodulin kinase ¢ò, CaMK ¢ò)ÔÚÐÄË¥ÖлîÐÔ¼°±í´ï¾ùÏÔ×ÅÔöÌí¡£Ê¹×ª»ùÒòСÊóµÄÐÄÔàÌ«¹ý±í´ïCaMK¢òµÄϸ°ûÖÊÑÇÐÍ £¬¿ÉÒÔÊӲ쵽×óÊҷʺñ¼°×óÊÒÀ©ÕÅ £¬²¢Öð²½Ï£ÍûΪÐÄÁ¦Ë¥½ß¡£

¼¡¶¯ÂѰ׻ùÒòת»ùÒòСÊ󣺼¡¶¯ÂѰ׻ùÒòת»ùÒòСÊó(mActin-Tg £¬ÒÑÔÚÀ©ÕÅÐÍÐ¡»¼ÕßÖб¨µÀ¹ýµÄÍ»±ä»ùÒò£©ÖÐСÊóµÄ×óÐÄÊÒÖð½¥±¬·¢À©Õź͹¦Ð§Õϰ­ £¬×îÖÕ¿ÉÒòÐÄÁ¦Ë¥½ß¶øéæÃü¡£

1£­°±»ù»·±ûÍé»ù£­1£­ôÈËáºÏ³Éø1ת»ùÒòСÊó£ºÊ¹Óü¡ÇòÂѰ×ÖØÁ´»ùÒòÆô¶¯×Óʹת»ùÒòÊóÔÚÐÄÔàÖÐÌ«¹ý±í´ï1£­°±»ù»·±ûÍé»ù£­1£­ôÈËáºÏ³Éø1 £¬¿É½¨Éè´úлÐÔÐ¡ÊóÄ£×Ó¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

¼¡ÈâlimÂѰ׻ùÒòÌÞ³ýСÊó×÷ΪÐÄË¥µÄÒÅ´«Ä£×Ó¿ÉÓÃÀ´Ì½Ë÷ÐÄË¥ºÍÀ©ÕÅÐ¡µÄ·Ö×ÓÖÎÁÆÒªÁì¡£1£­°±»ù»·±ûÉÕ»ù£­1- ôÈËáºÏ³Éø1ת»ùÒòÊóÄ£×Ó¿É×÷Ϊ֬ÖÊ´úлÒì³£µÄHFÄ£×Ó £¬ÓÐÖúÓÚÆÊÎöÖ¬Öʶ¾ÐÔHFµÄϸ°û»úÖÆ £¬ÎªÒ©ÀíѧʵÑéºÍ»ùÒòÕü¾ÈÕ½ÂÔÌṩÑо¿Ä£×Ó¡£×ª»ùÒòÐÄ˥ģ×ÓÒ²¿ÉÓÃÓÚÏàʶÓëÐÄË¥ÓйصĻùÒòÒÔ¼°Îª»ùÒòÖÎÁÆÌṩÒÀ¾Ý¡£Æäȱ·¦Ö®´¦ÊDz»¿ÉÖÜÈ«·´Ó¦ÁÙ´²ÉÏÐÄË¥»¼ÕßµÄÕæÊµ²¡Òò¡¢²¡ÀíÇéÐΡ£

 

²Î¿¼ÎÄÏ×£º

1.ÍõÁÁ £¬Öì±ø £¬ºÎÀ¥ÂØ£®ÂýÐÔȱѪÐÔÊæÕÅÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ӵĽ¨Éè.Öлª±£½¡Ò½Ñ§ÔÓÖ¾ £¬2010, 12 (l):19-22

2.Áõбö £¬ÀîÁ¦ £¬Õź쳬£®ÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ÓÑо¿Ï£Íûҽѧ×ÛÊö £¬2011, 17(11):1601-1604

3.ËïÑÞÏÀ £¬Íõ¹ú¸É£®ÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾ £¬2011,21 (7):73-78

4.ÕžùÌï.  ÏÖ´úÒ©ÀíʵÑéÒªÁ죮±±¾©£º±±¾©Ò½¿Æ´óѧÖйúЭºÍÒ½¿Æ´óѧÍŽá³öÊéÉç £¬1998

5.Õźê £¬Åí³É £¬Õ¹º£Ï¼ £¬µÈ£®Ò»ÖÖ´óÊó¼±ÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁ죮ËÄ´¨¶¯Îï £¬2008, 27 (2):296-298

6.ÐìÊåÔÆ £¬±åÈçå¥ £¬³ÂÐÞ£®Ò©ÀíʵÑéÒªÁìѧ£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉç £¬2005

7.¹ùÔ¥ÌΣ®³äѪÐÔÐÄÁ¦Ë¥½ßµÄ¶¯ÎïÄ£×Ó£®ÉϺ£ÊµÑ鶯Îï¿ÆÑ§ £¬2001, 21 (2):122-126

8.Braun MU, Szalai P,Strasser RH, el al£®Right ventricular hypertrophy and apoptosis after pulmonary artery bancling: regulation of PKC isozymes. Cardiovascular Res,2003, 59 (3):658-667

9.Rose M,ilalakumar P, Singh M, el al. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overloaded-induced cardiac hypertrophy in rat,.Pharmacology, 2007, 80 (2 3):177-184

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÐÄѪ¹Üϵͳģ×Ó > »ùÒòÐÞÊÎÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×Ó
»ùÒòÐÞÊÎÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×Ó

ǰÑÔ

ÐÄÁ¦Ë¥½ß(heart failure, HF)ÊÇÖ¸ÐÄÔà±ÃѪÄÜÁ¦¼õÍË £¬²»¿É²«³öÓë¾²Âö»ØÁ÷¼°ÉíÌå×éÖ¯´úлËùÐèÏ൱µÄѪҺ¹©Ó¦ £¬Í¬Ê±¾²ÂöϵͳÓÙѪµÄ²¡ÀíÀú³Ì¡£³£ÓÉÖÖÖÖ¼²²¡ÒýÆðÐļ¡Ëõ¶ÌÄÜÁ¦Ï÷Èõ £¬´Ó¶øÊ¹ÐÄÔàµÄѪҺÊä³öÁ¿ïÔÌ­ £¬È±·¦ÒÔÖª×ã»úÌåµÄÐèÒª £¬²¢Óɴ˱¬·¢Ò»ÏµÁÐÖ¢×´ºÍÌåÕ÷¡£¿É·ÖΪѹÁ¦³¬¸ººÉÒýÆðµÄÐÄÁ¦Ë¥½ßѪÈÝÅú³¬¸ººÉÒýÆðµÄÐÄÁ¦Ë¥½ß¡¢»¯Ñ§ÒòËØÒýÆðµÄÐÄÁ¦Ë¥½ß¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ £»úÖÆ¡¿£º

ÀíÂÛÉϽ² £¬Ê¹ÓÃת»ùÒòÊÖÒÕʹijÖÖÒò×ÓÔÚÐļ¡ÖÐÌ«¹ý±í´ï £¬»òʹÓûùÒòÇóýÊÖÒÕʹÓëÐļ¡Ëõ¶Ì¹¦Ð§Ç×½üÏà¹ØµÄ»ùÒòȱʧ £¬¿Éµ¼ÖÂÐÄË¥¡£Ð¡Êó»ùÒòÓëÈËÀà¿¿½ü £¬²¢Ò×±»¸Ä±ä £¬ÇҸıäºóµÄ»ùÒò±í´ïÏà¶ÔÎȹÌ¡£ÏÖÔËÓûùÒòÇÃÈë¡¢ÌÞ³ý¼°×ÌÈÅÊÖÒÕ £¬Ê¹ÐÄÔàÌØÒì»ùÒò±í´ï¸Ä±ä £¬¿É½¨ÉèСÊó»ùÒòÐÞÊÎÐÔÐÄÁ¦Ë¥½ßÄ£×Ó¡£

¡¾ÔìÄ£ÌØµã¡¿£º

¼¡ÈâlimÂѰ׻ùÒòÇóýСÊ󣺼¡ÈâlimÂѰ×(muscle LIM protein, MLP£©µ÷Àí¼¡Èâ·Ö½â £¬ÌÞ³ýMLP»ùÒòµÄ´¿ºÏ×ÓСÊ󽫷ºÆðÓëÀ©ÕÅÐÍÐÄ ¼¡²¡ÀàËÆµÄ±íÐÍ £¬²¢ÓÐÐļ¡·Ê´ó¡¢¼äÖÊϸ°ûÔöÉúºÍÏËά»¯ £¬µ½³ÉÄêÉú³¤ÎªHF £¬ÓÐÓëÈËÀàHF½üËÆµÄѪÁ÷¶¯Á¦Ñ§ºÍÁÙ´²ÌåÕ÷¡£ÆäÌØµãÊÇ×óÊÒ¹¦Ð§²»È« £¬éæÃü¡£¼¡ÈâlimÂѰ׻ùÒòÌÞ³ýСÊó×÷ΪÐÄË¥µÄÒÅ´«Ä£×Ó±»Ðí¶àʵÑéÊÒÓÃÀ´Ì½Ë÷ÐÄË¥ºÍÀ©ÐIJ¡µÄ·Ö×ÓÖÎÁÆÒªÁì¡£

¸Æµ÷ÂѰ׼¤Ã¸¢òת»ùÒòСÊ󣺸Ƶ÷ÂѰ׼¤Ã¸¢ò(calmodulin kinase ¢ò, CaMK ¢ò)ÔÚÐÄË¥ÖлîÐÔ¼°±í´ï¾ùÏÔ×ÅÔöÌí¡£Ê¹×ª»ùÒòСÊóµÄÐÄÔàÌ«¹ý±í´ïCaMK¢òµÄϸ°ûÖÊÑÇÐÍ £¬¿ÉÒÔÊӲ쵽×óÊҷʺñ¼°×óÊÒÀ©ÕÅ £¬²¢Öð²½Ï£ÍûΪÐÄÁ¦Ë¥½ß¡£

¼¡¶¯ÂѰ׻ùÒòת»ùÒòСÊ󣺼¡¶¯ÂѰ׻ùÒòת»ùÒòСÊó(mActin-Tg £¬ÒÑÔÚÀ©ÕÅÐÍÐ¡»¼ÕßÖб¨µÀ¹ýµÄÍ»±ä»ùÒò£©ÖÐСÊóµÄ×óÐÄÊÒÖð½¥±¬·¢À©Õź͹¦Ð§Õϰ­ £¬×îÖÕ¿ÉÒòÐÄÁ¦Ë¥½ß¶øéæÃü¡£

1£­°±»ù»·±ûÍé»ù£­1£­ôÈËáºÏ³Éø1ת»ùÒòСÊó£ºÊ¹Óü¡ÇòÂѰ×ÖØÁ´»ùÒòÆô¶¯×Óʹת»ùÒòÊóÔÚÐÄÔàÖÐÌ«¹ý±í´ï1£­°±»ù»·±ûÍé»ù£­1£­ôÈËáºÏ³Éø1 £¬¿É½¨Éè´úлÐÔÐ¡ÊóÄ£×Ó¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

¼¡ÈâlimÂѰ׻ùÒòÌÞ³ýСÊó×÷ΪÐÄË¥µÄÒÅ´«Ä£×Ó¿ÉÓÃÀ´Ì½Ë÷ÐÄË¥ºÍÀ©ÕÅÐ¡µÄ·Ö×ÓÖÎÁÆÒªÁì¡£1£­°±»ù»·±ûÉÕ»ù£­1- ôÈËáºÏ³Éø1ת»ùÒòÊóÄ£×Ó¿É×÷Ϊ֬ÖÊ´úлÒì³£µÄHFÄ£×Ó £¬ÓÐÖúÓÚÆÊÎöÖ¬Öʶ¾ÐÔHFµÄϸ°û»úÖÆ £¬ÎªÒ©ÀíѧʵÑéºÍ»ùÒòÕü¾ÈÕ½ÂÔÌṩÑо¿Ä£×Ó¡£×ª»ùÒòÐÄ˥ģ×ÓÒ²¿ÉÓÃÓÚÏàʶÓëÐÄË¥ÓйصĻùÒòÒÔ¼°Îª»ùÒòÖÎÁÆÌṩÒÀ¾Ý¡£Æäȱ·¦Ö®´¦ÊDz»¿ÉÖÜÈ«·´Ó¦ÁÙ´²ÉÏÐÄË¥»¼ÕßµÄÕæÊµ²¡Òò¡¢²¡ÀíÇéÐΡ£

 

²Î¿¼ÎÄÏ×£º

1.ÍõÁÁ £¬Öì±ø £¬ºÎÀ¥ÂØ£®ÂýÐÔȱѪÐÔÊæÕÅÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ӵĽ¨Éè.Öлª±£½¡Ò½Ñ§ÔÓÖ¾ £¬2010, 12 (l):19-22

2.Áõбö £¬ÀîÁ¦ £¬Õź쳬£®ÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ÓÑо¿Ï£Íûҽѧ×ÛÊö £¬2011, 17(11):1601-1604

3.ËïÑÞÏÀ £¬Íõ¹ú¸É£®ÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾ £¬2011,21 (7):73-78

4.ÕžùÌï.  ÏÖ´úÒ©ÀíʵÑéÒªÁ죮±±¾©£º±±¾©Ò½¿Æ´óѧÖйúЭºÍÒ½¿Æ´óѧÍŽá³öÊéÉç £¬1998

5.Õźê £¬Åí³É £¬Õ¹º£Ï¼ £¬µÈ£®Ò»ÖÖ´óÊó¼±ÐÔÐÄÁ¦Ë¥½ß¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁ죮ËÄ´¨¶¯Îï £¬2008, 27 (2):296-298

6.ÐìÊåÔÆ £¬±åÈçå¥ £¬³ÂÐÞ£®Ò©ÀíʵÑéÒªÁìѧ£®±±¾©£ºÈËÃñÎÀÉú³öÊéÉç £¬2005

7.¹ùÔ¥ÌΣ®³äѪÐÔÐÄÁ¦Ë¥½ßµÄ¶¯ÎïÄ£×Ó£®ÉϺ£ÊµÑ鶯Îï¿ÆÑ§ £¬2001, 21 (2):122-126

8.Braun MU, Szalai P,Strasser RH, el al£®Right ventricular hypertrophy and apoptosis after pulmonary artery bancling: regulation of PKC isozymes. Cardiovascular Res,2003, 59 (3):658-667

9.Rose M,ilalakumar P, Singh M, el al. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overloaded-induced cardiac hypertrophy in rat,.Pharmacology, 2007, 80 (2 3):177-184

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿